Abstract: 4-Hydroxyphenyl-2H-indazol-5-ol compounds are estrogen receptor beta ligands that have immunomodulatory properties and increase oligodendrocyte survival, differentiation, and remyelination. The compounds, compositions, and kits are useful in the treatment of multiple sclerosis and endometriosis.

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract: Compositions comprising nanoparticles are described herein. At least a portion of the nanoparticles comprises a lipid and/or polymer which is water-insoluble, and an agent incorporated in the lipid and/or polymer. The nanoparticles are optionally associated with a surface of water-soluble particles which comprise a water-soluble compound. The polymer is optionally a polyanhydride. Further described herein are processes for preparing such compositions, comprising contacting a solution comprising the lipid and/or polymer dissolved in a non-aqueous solvent with an anti-solvent (in which the lipid and/or polymer and agent are insoluble) which is miscible with the non-aqueous solvent. Further described herein are uses of the compositions for nasal administration, and devices configured for nasal administration of the composition upon atomization.

Abstract: Methods are provided for targeting cancer cells that over-express voltage-gated sodium channels (VGSCs or “sodium channels”) and causing osmotic lysis of these cancer cells by initially inhibiting the sodium, potassium-adenosine triphosphatase (Na+, K+-ATPase or “sodium pump”), and then stimulating the VGSCs by pulsed magnetic field gradients to cause sodium and water to enter the cancer cells.

Abstract: In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.

Abstract: A porous particle, wherein the porous particle has a mass median aerodynamic diameter and a volume average particle diameter that satisfy expression: y?2x, where x denotes the mass median aerodynamic diameter and y denotes the volume average particle diameter, and the porous particle has a relative span factor (R.S.F) that satisfies expression: 0<(R.S.F)?1.5.

Abstract: The present invention relates to the field of compounds, and in particular to a probucol derivative, a preparation method therefor and use thereof, the probucol derivative having a structure represented by general formula I. The probucol derivative provided in the present invention can be used for the prevention and treatment of vascular diseases including diabetes, cardio-cerebrovascular diseases or complications thereof, and can be effectively used for reducing blood glucose, reducing blood lipid, reducing cholesterol, reducing body weight, reducing triglyceride, anti-inflammatory, and anti-oxidation, etc., having broad prospective applications.

Abstract: The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof

Abstract: The present invention relates to compounds for use in the prevention and/or treatment of PAR-related diseases, such as for example: pain and ocular disorders. More in particular, the present invention provides bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of pancreatitis-related pain, IBS (irritable bowel syndrome), IBD (inflammatory bowel disease), dry eye disease and conjunctivitis sicca. These inhibitors were found to have a different inhibitory profile compared to diphenyl guanidinophenylethylphosphonates leading to a more pronounced effect on these conditions.

Abstract: A method by which an intermediate product of an azole derivative can be produced at a lower cost and in a higher yield than those of known production methods is realized. A method of producing a compound of General Formula (III) includes: producing the compound of General Formula (III) by allowing a cyanide compound to act on a ketone derivative of General Formula (II); and washing the compound of General Formula (III) produced in the producing the compound of General Formula (III) with an alkaline aqueous solution.

Abstract: The disclosure relates to compounds and compositions for sustained release of ocular therapeutics.

Abstract: The present invention provides a method for producing an oxide catalyst containing antimony, comprising a step (A) of obtaining the oxide catalyst using antimony particles containing a diantimony trioxide as a source of the antimony, wherein an abundance of a pentavalent antimony in a surface layer of the antimony particle to be measured in XPS analysis is less than 70 atom %, and the antimony particle has an average particle size of 1.2 ?m or less.

Abstract: Silicone-in-water emulsions and methods for making same, are disclosed which are useful and effective as lubricants for use in intimate care applications, as a skin condition, as a surgical lubricant and/or as a carrier for an active topical pharmaceutical agent. In preferred examples, the emulsions of the present invention are flowable, have a viscosity of equal to or below about 15,000 centipoise (cP), and are stable upon storage for at least about 1 year.

Abstract: The present invention relates to a new class of fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.

Abstract: A method of preparing a disinfecting composition comprising charged polyethylenimine (PEI), the method comprising adding a base to an aqueous solution comprising a linear PEI hydrochloride solution to provide a linear PEI salt solution with a pH between 9-11, adding a first organic acid to reduce the pH to less than 7, removing about 20% to 100% of the salt from the solution, and optionally adding water and/or a second organic acid to obtain the disinfecting composition with a pH of 2-7. The method can further comprise adding at least one metal salt to the disinfecting composition. The resulting disinfecting solution can be used to provide antimicrobial products with enhanced antimicrobial performance, reduced toxicity, and/or able to leave a persistent “kill-later” film.

Abstract: The invention relates to the use of, and methods of use employing, certain glycolipid compounds as defined in detail below and having preservative or antimicrobial properties, novel compounds of the glycolipid class, and related invention embodiments. The compounds have the formula I wherein m is 3 to 5, n is 2 to 5, o is 0 or 1 and p is 3 to 17, with the proviso that the sum m+n+o+p is not less than 14; and R is a carbohydrate moiety bound via one of its carbon atoms to the binding oxygen, and/or a physiologically, especially pharmaceutically or nutraceutically or cosmetically, acceptable salt thereof, or an ester thereof, as such or in the form of a composition, where the compound may be present in open chain form and/or in the form of a lactone (FIG. 1).

Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, inhibitors of apoptosis proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Abstract: The present invention relates to lyso-diacylglyceryltrimethylhomoserine (lyso-DGTS) or derivatives thereof for use in the treatment of atherosclerotic cardiovascular disease, and further provides particular such lyso-DGTS derivatives.

Abstract: The present invention provides a method for producing fisetin or fisetin derivatives, which is capable of mass production. The method for producing fisetin or fisetin derivatives according to the present invention is capable of mass-producing fisetin or fisetin derivatives without a purification process such as a column chromatography process.

Abstract: The present invention provides a 2-polysubstituted aromatic ring-pyrimidine derivative and an optical isomer thereof, or a pharmaceutically acceptable salt or solvate thereof, the compound, and an optical isomer thereof or a pharmaceutically thereof acceptable salts or solvates can be used in the preparation of anti-tumor drugs. The invention designs and synthesizes a series of novel small molecule Chk1 inhibitors by using N-substituted pyridin-2-aminopyrimidine obtained by structure-based virtual screening as a lead compound, and carries out Chk1 kinase inhibitory activity test. The experiment confirmed that said compounds possess potent anticancer activity, Chk1 kinase inhibitory activity, and are promising Chk1 inhibitors, and can be used as new cancer therapeutic drugs, which can be applied to treat solid tumors or hematologic tumors related to proliferative disease of human or animal.